Key Highlights
- $1B strategic partnership unites Halda’s novel RIPTAC drug platform with VantAI’s generative AI proteomics engine.
- Accelerated pipeline: First-in-class RIPTAC candidate HLD-0915 already in Phase I/II trials with FDA fast track designation.
- Industry shift: Collaboration signals AI’s growing role in tackling previously “undruggable” cancer targets.
Strategic Alliance to Advance Induced Proximity Therapies
Halda Therapeutics has entered into a collaboration with AI biotech VantAI, valued up to $1B in milestone payments. The deal aims to expand cancer drug discovery through Halda’s regulated induced proximity targeting chimeras (RIPTACs) and VantAI’s structural proteomics platform.
AI-Driven Discovery Meets Novel RIPTAC Modality
VantAI’s Neo-1 AI engine predicts protein and molecular interactions at the atomic level. Integrated with Halda’s “hold and kill” RIPTAC mechanism, the platform seeks to rewire protein interactions and create bifunctional molecules capable of eliminating cancer cells.
Pipeline Impact: HLD-0915 and Beyond
Halda’s lead candidate HLD-0915, in Phase I/II for prostate cancer, has FDA fast track designation. Early data shows favorable therapeutic index, positioning RIPTACs as a next-generation oncology modality.
Industry Implications for AI in Oncology
This alliance highlights AI’s disruptive role in drug discovery. By merging computational platforms with novel therapeutic modalities, Halda and VantAI set a precedent for AI-driven oncology pipelines and accelerated patient impact.
About Halda Therapeutics
Halda Therapeutics is a clinical-stage biotechnology company developing a new class of precision medicines called Regulated Induced Proximity Targeting Chimeras (RIPTACs). Its lead candidate, HLD-0915, is currently in Phase I/II trials targeting advanced prostate cancer.
About VantAI
VantAI is a New York-based biotechnology company leveraging generative AI-driven structural proteomics to design next-generation therapeutics. Its proprietary Neo-1 and Neo Link platforms enable the prediction and engineering of complex protein interactions at atomic resolution.
By